Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Pandoraon Jul 19, 2023 12:19am
323 Views
Post# 35547285

RE:RE:RE:Waiting continues

RE:RE:RE:Waiting continues
The application rejected in January had 32 claims. One claim was withdrawn and the other 31 were given a non-final rejection. A few claims are based on a requirement for wording changes. The majority of the rest are a conflict with a prior application by guess who? Arkady Mandel. Presumably their recent arguments resolved that conflict. There are however a few claims in conflict with a person named Goodrich. i.e. another prior application. I cannot find out who that is but presumably the Company knows all that and has resolved that conflict as well, seeing as they have submiited arguments and that is why they have asked for reconsideration.

The non-final rejection process is quite standard. All, or almost all, patent applications go through it. Examiners are tough and find all kinds of what they consider conflicts or prior art.

I can't say if it's a great cure. That's what trials are for.
<< Previous
Bullboard Posts
Next >>